QUOTED. 19 July 2019. Miles White.
Executive Summary
Abbott Laboratories plans to invest significantly to expand manufacturing capacity for its FreeStyle Libre continuous glucose monitoring system in an effort to meet demand. See what Abbott CEO Miles White said about it here.
"The first wave of that expansion will come online in the next couple of months, followed by a cadence of incremental capacity after that. There's a massive population that needs help managing their diabetes and our intent is to make Libre broadly accessible to all of them." – Miles White, CEO, Abbott Laboratories Inc.
Click here for a free trial of Medtech Insight